NCT02381132View on ClinicalTrials.gov

A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain

PHASE3TerminatedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Post Operative Pain
Interventions
DRUG

Norco 7.5mg/325

DRUG

MNK155

Trial Locations (1)

91105

Lotus Clinical Research, LLC, Pasadena

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Neil Singla

OTHER

NCT02381132 - A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain | Biotech Hunter | Biotech Hunter